OncLive TV

Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

Joshua Richter, MD, discusses the FDA approval of linvoseltamab for relapsed or refractory multiple myeloma.

Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.

Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Gilberto Lopes, MD, MBA, FAMS, discusses findings from a cost-effectiveness analysis of osimertinib/chemotherapy vs amivantamab/lazertinib in EGFR-mutated NSCLC.

John O. Mascarenhas, MD, discusses important factors to consider when evaluating patients for clinical trial enrollment in myelofibrosis.

Laura A. Huppert, MD, discusses how the approval of the SERENA-6 regimen could affect second-line treatment decision-making in HR-positive breast cancer.

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.

Alexey Danilov, MD, PhD, discusses frontline treatment selection for chronic lymphocytic leukemia.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Prerna Mewawalla, MD, explains the roles of cilta-cel and ide-cel in clinical practice for the treatment of relapsed/refractory multiple myeloma.

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Cyrus M. Khan, MD, discusses how zanubrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.